TheraRadar
← Back
Data updated: Mar 29, 2026

SYNTHON PHARMS

NeurologyCardiovascularMetabolic
Generics

SYNTHON PHARMS is a generic drug manufacturer focused on Neurology, Cardiovascular, Metabolic.

2001
Since
9
Drugs
-
Trials
101
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

AMLODIPINE BESYLATE 2026-02-17
Manufacturing (CMC)
GLATIRAMER ACETATE 2026-02-11
GLATIRAMER ACETATE 2026-02-11
AMLODIPINE BESYLATE 2026-01-26
Manufacturing (CMC)
AMLODIPINE BESYLATE 2026-01-22
GLATIRAMER ACETATE 2025-12-31
RISPERIDONE 2025-11-04
Labeling
LETROZOLE 2025-10-24
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 33%
1 drugs
Cardiovascular 33%
1 drugs
Metabolic 33%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novo Nordisk big-pharma
Metabolic, Cardiovascular, Neurology
UPJOHN big-pharma
Neurology, Cardiovascular, Metabolic
AZURITY specialty
Cardiovascular, Neurology, Metabolic
Merck big-pharma
Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Cardiovascular, Metabolic